


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:






1. (Previously Presented) A compound of formula (I):



(I)

wherein:

R¹ represents a group selected from:



each ring of which optionally includes a further heteroatom N,

Z represents an optional substituent halogen,

alk represents alkylene or alkenylene,

T represents S, O or NH;

R² represents hydrogen, -C₁₋₆alkyl, -C₁₋₃alkylCONR^aR^b, -C₁₋₃alkylCO₂C₁₋₄alkyl, -CO₂C₁₋₄alkyl or -C₁₋₃alkylCO₂H;

R^a and R^b independently represent hydrogen, -C₁₋₆alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally consisting of an additional heteroatom selected from O, N or S(O)_n, optionally substituted by -C₁₋₄alkyl;

n represents 0-2;

X represents phenyl or a 5- or 6- membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C₁₋₄alkyl, -C₂₋₄alkenyl, -CN, -CF₃, -NR^aR^b, -C₀₋₄alkylOR^e, -C(O)R^f and -C(O)NR^aR^b;

R^e represents hydrogen or -C₁₋₆alkyl;


R^f represents -C₁₋₆alkyl;

Y represents phenyl or a 5- or 6- membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is substituted by a group -C₁₋₂alkylNR^cR^d.

R^c and R^d, together with the nitrogen atom to which they are bonded, form a 4-membered heterocyclic ring optionally substituted by halogen, OH or -OC₁₋₆alkyl, or a 5- or 6- membered non-aromatic heterocyclic ring substituted by OH, -OC₁₋₆alkyl or 1 to 2 halogens, with the proviso that the substituent is not attached to a ring carbon atom adjacent to a heteroatom;

or pharmaceutically acceptable derivative thereof.

2. (Original) A compound according to claim 1 wherein R^1 represents a group selected from:



each ring of which optionally includes a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH;
or pharmaceutically acceptable derivative thereof.

3. (Previously Presented) A compound according to claim 1 wherein R^2 represents hydrogen or pharmaceutically acceptable derivative thereof.
4. (Previously Presented) A compound according to claims 1 wherein X represents phenyl or a 5 or 6 membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, $-C_{1-4}alkyl$ or $-NR^aR^b$ or pharmaceutically acceptable derivative thereof.
5. (Previously Presented) A compound according to claim 1 wherein Y represents a 5 or 6 membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is substituted by a group $-CH_2NR^cR^d$ or pharmaceutically acceptable derivative thereof.
6. (Previously Presented) A compound selected from:
(1E)-N-(1-{4-[2-(1-Azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)-1-propene-1-sulfonamide;

N-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)ethanesulfonamide;
N-((3*S*)-1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-6-chloro-1-benzothiophene-2-sulfonamide;
(*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl})phenyl]-2-oxo-3-pyrrolidinyl]ethanesulfonamide;
(1*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl})phenyl]-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide;
6-Chloro-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl})phenyl]-2-oxo-3-pyrrolidinyl]-1-benzothiophene-2-sulfonamide; and
6-Chloro-*N*-{1-[2-fluoro-4-(2-{[3-(methyloxy)-1-azetidiny]methyl}-1*H*-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl}-1-benzothiophene-2-sulfonamide formate;
or a pharmaceutically acceptable derivative thereof.

7. (Cancelled).



8. (Previously Presented) A pharmaceutical composition comprising a compound according to claims 1 or a pharmaceutically acceptable derivative thereof together with at least one pharmaceutical carrier or excipient.

9. (Cancelled).

10. (Currently Amended) A method of treating a ~~patient suffering from a~~ condition susceptible to amelioration by a Factor Xa inhibitor, wherein said condition is one or more of acute coronary syndromes, prothrombotic sequelae associated with myocardial infarction or heart failure, thromboembolism, acute vessel closure associated with thrombolytic therapy and percutaneous transluminal coronary angioplasty, transient ischemic attacks, pulmonary embolism, deep vein thrombosis, peripheral arterial occlusion, restenosis, and thromboembolic events associated with atrial fibrillation including stroke, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable derivative thereof.

11. (Currently Amended) A process for preparing a compound ~~of formula (I)~~ as claimed in claim 1, which comprises:

(a) reacting a compound of formula (II) or an acid addition salt thereof with a compound of formula (III) where V is a suitable leaving group:



OR:

(b) by reacting compounds of formula (I) where R² is hydrogen with compounds of formula (XI):



wherein R² is -C₁₋₆alkyl, -C₁₋₃alkylCONR^aR^b, -C₁₋₃alkylCO₂C₁₋₄alkyl, or -CO₂C₁₋₄alkyl and T is a suitable leaving group, optionally followed by removal of the alkyl protecting group where appropriate.